Overview
OVERVIEW
Zusamen Lifesciences & Research Pvt. Ltd. (Zusamen) is the latest and most ambitious venture of the Libra Group of Companies. It will facilitate a multi-fold scaling up of the Group’s manufacturing capabilities in terms of capacities and dosage forms.
Zusamen was incorporated on 20th January, 2014 with the primary objective of setting up a world-class state-of-the-art manufacturing facility for pharmaceutical formulations for both the domestic and export markets.
Zusamen is a brand new state-of-the-art pharma formulations manufacturing facility designed & constructed as per FDA / WHO standards. The facility is in the final stage of completion and is designed to conform to PIC/S standards with minor up-gradation as and when demanded by business considerations.
The Libra Group of Companies
Libra Drugs (India)
This is the parent company of the group and is in existence since 1962. It is a pharma company manufacturing branded formulations for domestic as well as for export markets.
Drugs Land
This is a pharma export house marketing its branded formulations in various countries including Mauritius, Ivory coast, Guyana, Guinea Bissau, Kenya, Sri Lanka and South Sudan. The merchant exporter company is in existence since 1988.
Libra Drugs (India) Pvt. Ltd.
This company markets its branded formulations in the domestic market with a dedicated marketing team in Maharashtra, Karnataka & Orissa. The company was established in 1984.
The Facility Incorporates Manufacturing Lines For The Following Dosage Forms
Tablets
Creams & Ointments
Hard Gelatin Capsules
Liquid (Orals)
The facility is presently in the stage of completing various pre-licensing tests, operations & other formalities including completion of all required documentation, qualifications & validations. FDA Certification / License is expected to be in place latest by end June, 2019 and commercial operations are scheduled to commence shortly thereafter. Certifications by WHO and PIC/S authorities are proposed to be sequentially obtained within a period of six and eighteen months from the start of commercial operations, i.e. by early 2020 and early 2021 respectively.